The Innovation Passport is a significant regulatory milestone that can significantly accelerate the time to market for Sebetralstat. This development is likely to be viewed positively by investors, as it represents progress in the drug's development pathway and potential for early market access in the UK, which could lead to increased investor confidence and potential stock price appreciation in the short term.